Juvenile Dermatomyositis

Claas Hinze; Frank Dressler; Ulrike Schara-Schmidt; Johannes-Peter Haas

doi:10.1055/a-1769-4299

Aktuelle Rheumatologie, Inhaltsverzeichnis

Aktuelle Rheumatologie 2022; 47(02): 99-109
DOI: 10.1055/a-1769-4299

Übersichtsarbeit

Juvenile Dermatomyositis

Juvenile dermatomyositis

Claas Hinze

¹Klinik für Pädiatrische Rheumatologie und Immunologie, Universitätsklinikum Münster, Münster, Germany

,

Frank Dressler

²Klinik für Pädiatrische Pneumologie, Allergologie und Neonatologie, Medizinische Hochschule Hannover, Hannover, Germany

,

Ulrike Schara-Schmidt

³Abteilung für Neuropädiatrie, Zentrum für Neuromuskuläre Erkrankungen im Kindes- und Jugendalter, Universitätsklinikum Essen, Essen, Germany

,

Johannes-Peter Haas

⁴German Center for Rheumatology in Children and Adolescents, Deutsches Zentrum für Kinder- und Jugendrheumatologie Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany

⁵Center for treatment of pain in young people, Zentrum für Schmerztherapie junger Menschen, Garmisch-Partenkirchen, Germany

› Institutsangaben

Abstract

Zusammenfassung

Die juvenile Dermatomyositis (JDM) ist die häufigste chronische entzündliche Myopathie des Kindesalters. In dieser Übersicht soll der aktuelle Kenntnisstand hinsichtlich der Diagnostik, Behandlung und Überwachung der JDM dargestellt werden. So liegen häufig myositis-spezifische Antikörper vor, die mit klinischen Phänotypen und dem Verlauf der Erkrankung korrelieren. Typ I Interferone spielen eine wichtige Rolle in der Pathogenese der Erkrankung. Möglicherweise kann diese Beobachtung in der Zukunft zu gezielten Therapien führen. Da langfristig schwerwiegende Komplikationen, wie z. B. Kalzinosen oder Lipodystrophie, drohen, besonders bei auf Dauer unzureichend kontrollierter Erkrankung, ist eine möglichst rasche und effektive Behandlung anzustreben. Zu diesem Zweck sollte eine intensive Remissionsinduktionstherapie, gefolgt von einer zielgerichteten Therapie angestrebt werden. Verschiedene validierte Messinstrumente stehen zur Verfügung, um den Verlauf der Erkrankung zu beurteilen. Die Pro-KIND-Initiative der Gesellschaft für Kinder- und Jugendrheumatologie hat Praxis- und Konsens-basiert in Deutschland sowohl eine diagnostische als auch eine Treat-to-Target-Behandlungsstrategie entwickelt. Im Rahmen nationaler und internationaler Kollaborationen soll sich die Behandlung der JDM in der Zukunft weiter verbessern.

Abstract

Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy of childhood. In this review, the current state of knowledge concerning diagnostic testing, treatment and monitoring of JDM are illustrated. Myositis-specific antibodies are frequently observed, which may correlate with the disease phenotype and course. Furthermore, type 1 interferons play an important pathophysiological role in JDM. This may potentially lead to targeted therapies in the future. In the context of uncontrolled disease activity, serious complications may arise in the long term, such as calcinosis or lipodystrophy. Rapid implementation of efficacious treatment is therefore desirable. For this purpose, an intensive remission induction regimen is usually implemented, followed by a treat-to-target strategy. Multiple validated monitoring tools are available in order to gauge treatment response. The Pro-KIND project of the German Society for Pediatric and Adolescent Rheumatology has established practice- and consensus-based diagnostic and treat-to-target strategies. In the context of national and international collaboration, the management of JDM should be improved in the future.

Schlüsselwörter

Juvenile Dermatomyositis - Entzündliche Myopathie - Myositisspezifische Antikörper

Key words

juvenile dermatomyositis - inflammatory myopathy - myositis-specific antibodies

Volltext

Referenzen

Literatur
1 Feldman BM, Rider LG, Reed AM. et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371: 2201-2212
2 Dressler F, Frosch M, Monkemoller K. et al. Results of the German ESPED-recording of new patients with juvenile dermatomyositis (JDM). Klinische Padiatrie 2011; 223: 280-282
3 Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34: 732-736
4 Mendez EP, Lipton R, Ramsey-Goldman R. et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis and rheumatism 2003; 49: 300-305
5 Horn S, Minden K, Speth F. et al. Myositis-specific autoantibodies and their associated phenotypes in juvenile dermatomyositis: data from a German cohort. Clinical and experimental rheumatology. 2020
6 Rider LG, Shah M, Mamyrova G. et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 2013; 92: 223-243
7 Yamasaki Y, Kobayashi N, Akioka S. et al. Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study. Rheumatology 2021; 60: 4821-4831
8 Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. Journal of internal medicine 2016; 280: 24-38
9 Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?. Arthritis Res Ther 2013; 15: 211
10 Della Marina A, Pawlitzki M, Ruck T. et al. Clinical Course, Myopathology and Challenge of Therapeutic Intervention in Pediatric Patients with Autoimmune-Mediated Necrotizing Myopathy. Children (Basel) 2021; 8
11 Klein M, Mann H, Plestilova L. et al. Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology 2015; 54: 2010-2014
12 Kim H. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy. Curr Opin Rheumatol 2021; 33: 371-377
13 Kim H, Gunter-Rahman F, McGrath JA. et al. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther 2020; 22: 69
14 Lerkvaleekul B, Veldkamp SR, van der Wal MM. et al. Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. Rheumatology 2021;
15 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). The New England journal of medicine 1975; 292: 344-347
16 Hinze CH, Oommen PT, Dressler F. et al. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. Pediatric rheumatology online journal 2018; 16: 40
17 Hinze CH, Speth F, Oommen PT. et al. Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists. Pediatric rheumatology online journal 2018; 16: 38
18 Lundberg IE, Tjarnlund A, Bottai M. et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76: 1955-1964
19 Morris P, Dare J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. Journal of pediatric hematology/oncology 2010; 32: 189-191
20 Huber AM, Robinson AB, Reed AM. et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis care & research 2012; 64: 546-553
21 Rider LG, Werth VP, Huber AM. et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis care & research 2011; 63: S118-S157
22 Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis and rheumatism 2008; 58: 3585-3592
23 Lam CG, Manlhiot C, Pullenayegum EM. et al. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Annals of the rheumatic diseases 2011; 70: 2089-2094
24 Bingham A, Mamyrova G, Rother KI. et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine 2008; 87: 70-86
25 Ravelli A, Trail L, Ferrari C. et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis care & research 2010; 62: 63-72
26 Sanner H, Aalokken TM, Gran JT. et al. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Annals of the rheumatic diseases 2011; 70: 86-91
27 Schwartz T, Sanner H, Husebye T. et al. Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Annals of the rheumatic diseases 2011; 70: 766-771
28 Enders FB, Bader-Meunier B, Baildam E. et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Annals of the rheumatic diseases 2016;
29 Rider LG, Aggarwal R, Pistorio A. et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 2017; 69: 911-923
30 Ruperto N, Pistorio A, Oliveira S. et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 2016; 387: 671-678
31 Huber AM, Giannini EH, Bowyer SL. et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis care & research 2010; 62: 219-225
32 Oddis CV, Reed AM, Aggarwal R. et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis and rheumatism 2013; 65: 314-324
33 Aggarwal R, Bandos A, Reed AM. et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis & rheumatology 2014; 66: 740-749
34 Ll Wilkinson MG, Deakin CT, Papadopoulou C. et al. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatric rheumatology online journal 2021; 19: 146
35 Voyer TL, Gitiaux C, Authier FJ. et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology 2021;
36 Kim H, Dill S, O'Brien M. et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Annals of the rheumatic diseases 2020;
37 Riisager M, Mathiesen PR, Vissing J. et al. Aerobic training in persons who have recovered from juvenile dermatomyositis. Neuromuscular disorders: NMD 2013; 23: 962-968
38 Habers GE, Bos GJ, van Royen-Kerkhof A. et al. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. Rheumatology 2016; 55: 1251-1262
39 Speth F, Wellinghausen N, Haas JP. Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2. Zeitschrift fur Rheumatologie 2013; 72: 896-909
40 Mamyrova G, Kishi T, Targoff IN. et al. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology 2018; 57: 1956-1963
41 Miles L, Bove KE, Lovell D. et al. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis and rheumatism 2007; 57: 1183-1191
42 Deakin CT, Yasin SA, Simou S. et al. Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. Arthritis &. rheumatology 2016; 68: 2806-2816
43 Ladd PE, Emery KH, Salisbury SR. et al. Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome. AJR Am J Roentgenol 2011; 197: W153-W158
44 Lang B, Dooley J. Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. The Journal of pediatrics 1996; 128: 429-432
45 Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis and rheumatism 1987; 30: 328-334
46 Klein-Gitelman MS, Waters T, Pachman LM. The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis care and research : the official journal of the Arthritis Health Professions Association 2000; 13: 360-368
47 Rouster-Stevens KA, Morgan GA, Wang D. et al. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis care & research 2010; 62: 1446-1451
48 Jacobs JC. Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics 1977; 59: 212-218
49 Deakin CT, Campanilho-Marques R, Simou S. et al. Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. Arthritis & rheumatology 2018; 70: 785-793
50 Al-Mayouf SM, Laxer RM, Schneider R. et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. The Journal of rheumatology 2000; 27: 2498-2503
51 Speth F, Haas JP, Hinze CH. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. Pediatric rheumatology online journal 2016; 14: 52
52 Rouster-Stevens KA, Ferguson L, Morgan G. et al. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis care & research 2014; 66: 783-787
53 Campanilho-Marques R, Deakin CT, Simou S. et al. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther 2020; 22: 79